WITH REJUVE, YOU WILL IMPROVE
Live / Allowed — Notice of allowance issued (as of 02 Sept 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 11 Jul 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98644838
- Mark type
- Stylized text
- Filed
- 11 Jul 2024
- Published for opposition
- 08 Jul 2025
Goods and services
- Class 005 — Pharmaceuticals: Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical preparations for the treatment of COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical preparations for preventing, diagnosing, treating and managing cancer, fibrotic diseases, NASH, Crohn's Disease, osteoarthritis, viral infections, and hepatitis C; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Inhalers for medical purposes, sold filled with pharmaceutical preparations for treating COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical preparations for treating asthma
- Class 042 — Scientific and technological services: Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer
Owner
- Rejuve Therapeutics, Inc., Houston, TX, US
- Rejuve Therapeutics, Inc., Houston, TX, US
Prosecution history
- 02 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Jul 2025 — PUBLISHED FOR OPPOSITION
- 02 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 04 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Jun 2025 — EXAMINER'S AMENDMENT ENTERED
- 02 Jun 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 02 Jun 2025 — EXAMINERS AMENDMENT E-MAILED
- 02 Jun 2025 — EXAMINERS AMENDMENT -WRITTEN
- 03 Feb 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 03 Feb 2025 — NON-FINAL ACTION E-MAILED
- 03 Feb 2025 — NON-FINAL ACTION WRITTEN
- 03 Feb 2025 — ASSIGNED TO EXAMINER
- 02 Feb 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 12 Jul 2024 — NEW APPLICATION ENTERED